Product
Supplier
Encyclopedia
Inquiry
Osimertinib    1421373-65-0 buy - large image1
Osimertinib    1421373-65-0 buy - image1

Osimertinib 1421373-65-0

2 Inquiries

Unit Price: Get Latest Price
CAS No.:

1421373-65-0

Content:

99%

Port:

shanghai

Packaging:

1kg/drum

Price valid (until):

2025-01-07

Company Type:
Trader
Location:
China
Qualification:
Main Products:

13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1,2-DICARBOXYLIC ACID DIMETHYL ESTER, TRANS

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Osimertinib (previously known as mereletinib or AZD9291; trade name Tagrisso) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals – for mutated EGFR cancers.

    Basic Info
    Product Name:

    Osimertinib

    Other Name:

    2-Propenamide,N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide;AZD 9291;Osimertinib;Tagrisso;1610419-47-0

    CAS No.:

    1421373-65-0

    Molecular Formula:

    C28H33N7O2

    InChIKeys:

    InChIKey=DUYJMQONPNNFPI-UHFFFAOYSA-N

    Molecular Weight:

    499.61

    Exact Mass:

    499.61

    UNII:

    3C06JJ0Z2O

    NCI Thesaurus Code:

    C116377

    ATC Code:

    L01XE|L - Antineoplastic and immunomodulating agents

    HScode:

    29339900

    Characteristics
    PSA:

    87.6

    XLogP3:

    3.7

    Density:

    1.19±0.1 g/cm3(Predicted)

    Refractive Index:

    1.618

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1,2-DICARBOXYLIC ACID DIMETHYL ESTER, TRANS

    Location:

    Room 1623,Building A, ZhongqiaoCenter,Goverment District,Hefei city,Anhui Province,China

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    5-10

    Year of Establishment:

    2019

  • Inquiry History
    2 Inquiries
    Country Product Purchase Quantity Date Posted
    Puerto Rico

    Osimertinib

    1 KG May 29, 2025
    Bangladesh

    Osimertinib

    1 MT Sep 9, 2024
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.